ProShares Ultra NASDAQ Biotechnology
BIB
BIB
25 hedge funds and large institutions have $8.16M invested in ProShares Ultra NASDAQ Biotechnology in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 0 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
30% less capital invested
Capital invested by funds: $11.6M → $8.16M (-$3.46M)
Holders
25
Holding in Top 10
–
Calls
$1.6M
Puts
$1.42M
Top Buyers
| 1 | +$221K | |
| 2 | +$74K | |
| 3 | +$42.4K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$27.3K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
+$20K |
Top Sellers
| 1 | -$1.61M | |
| 2 | -$1.56M | |
| 3 | -$136K | |
| 4 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
-$32.5K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$21.6K |